Webinar Date/Time: Thursday, May 23, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
Gain insight from this webinar series on leveraging technology to optimize clinical trial protocols and outcomes that comply with stringent regulatory requirements.
Register Free: https://www.pharmexec.com/pe/data-ecosystem
Event Overview:
Significant advances in technology are providing new opportunities to collect and utilize real-world data to establish better clinical trial protocols that have a patient-centric focus and the ability to transform healthcare. However, it is important to understand how such applications work and their impact on safety.
This webcast series uncovers the concerns of safety professionals and other stakeholders involved in the development and implementation of clinical trial protocols in the digital era and highlights methods to best apply digital data into routine practice to best optimize trial success and adhere to strict regulatory guidance.
Key Learning Objectives
Who Should Attend
Full Agenda
Thursday, May 23rd:
10:00 am EDT Oracle and Cerner: A Leap Forward in Safety
Michael Fronstin, Global Head of Clinical Research and Consulting; Oracle Cerner Enviza
Bruce Palsulich, Vice President of Product Strategy; Oracle Health Sciences
11:00 am EDT Automating Study Setup with a Digital Data Flow
Julie Smiley, Sr. Director, Life Sciences Product Strategy; Oracle, and other non-Oracle speakers.
12:00 pm EDT Building a Thriving Culture of Innovation in Pharmacovigilance
Non-Oracle speakers
Speakers:
Michael Fronstin
Global Head of Clinical Research and Consulting
Oracle Cerner Enviza
Bruce Palsulich
Vice President of Product Strategy
Oracle Health Sciences
Julie Smiley
Sr. Director, Life Sciences Product Strategy
Oracle
Register Free: https://www.pharmexec.com/pe/data-ecosystem
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.